Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.57 |
| ▸ | TCF7 | P36402 | 2/20 | 0.57 |
| ▸ | BCL9 | O00512 | 1/20 | 0.57 |
| ▸ | TCF4 | P15884 | 1/20 | 0.57 |
| ▸ | CLPP | Q16740 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23804489 | 1.00 | CYP3A4 (0.58) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL30343331 | 0.92 | TCF4 (0.52) | CYP3A4CTNNB1TCF4CLPP | |
| SCHEMBL23804486 | 0.92 | TCF4 (0.52) | CYP3A4CTNNB1TCF4CLPP | |
| SCHEMBL747054 | 0.91 | CTNNB1 (0.57) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL763057 | 0.91 | CTNNB1 (0.69) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL749449 | 0.88 | CYP3A4 (0.52) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL10227750 | 0.88 | CYP3A4 (0.54) | CYP3A4 | |
| SCHEMBL12222064 | 0.88 | CYP3A4 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL750548 | 0.88 | CTNNB1 (0.61) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13712377 | 0.88 | CTNNB1 (0.61) | CYP3A4CTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835865-A | CBP/catenin signal transmission path inhibitor and application thereof | 3+2 制药有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2023027888-A1 | PYRAZOLE-CONTAINING CBP/CATENIN ANTAGONISTS AND USES THEREOF | 3+2 PHARMA, LLC (US) | 2023-03-02 | — | — | WO | disclosed |
| EP-4117663-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 Pharma LLC (US) | 2023-01-18 | — | — | EP | disclosed |